PODD earnings call for the period ending June 30, 2020.
News & Analysis: Insulet
As the prevalence of diabetes has grown, these companies are looking for solutions.
Here’s why a company making an essential and widely popular insulin pump is a solid buy amidst the backdrop of the COVID-19 pandemic.
The COVID-19 pandemic is presenting a headwind, but Insulet's recurring-revenue-generating business model helps insulate it.
These four companies have tremendous growth potential going into 2020.
PODD earnings call for the period ending March 31, 2020.
Shares of the tubeless insulin pump maker are also outperforming the market in 2020.
Stocks of companies getting a direct tailwind from the COVID-19 pandemic aren't the only top performers in 2020 and over the last year.
Despite last month's decline, shares of the leader in tubeless insulin pump technology are significantly outperforming the market in 2020.
Investors are optimistic about a potential federal stimulus bill.